1. Introduction

The Australian Securities Exchange (ASX) Corporate Governance Principles and Recommendations provide a framework for responsible management, transparency, accountability and investor protection in listed companies. For biotechnology firms, these principles are particularly important because their operations involve scientific uncertainty, clinical-trial risks, intellectual property, regulatory approvals, substantial research expenditure and potentially life-changing products.

An ASX-listed biotechnology company may develop gene therapies, vaccines, diagnostic tests, medical devices, cell therapies or genetically modified products. Corporate governance must therefore address both conventional corporate risks and scientific, clinical, bioethical and regulatory risks.

The principal framework is the ASX Corporate Governance Principles and Recommendations, 4th edition (2019), together with the Corporations Act 2001 (Cth), ASX Listing Rules, applicable therapeutic-goods legislation and relevant scientific research requirements.

Important distinction: The ASX Principles are not themselves a comprehensive statute or a biotechnology-specific code. They operate primarily through an “if not, why not” disclosure framework for ASX-listed entities. Binding legal duties arise from legislation, listing rules and other applicable regulatory obligations.

2. The eight ASX corporate governance principles

The fourth edition remains the operative edition as of 23 October 2026. ASX has consulted on a proposed fifth edition, but the fourth edition has not yet been replaced.

Australian Securities Exchange

+1

Principle 1 — Lay solid foundations for management and oversight

Establish clear responsibilities for directors, executives and management. Biotechnology boards should define who approves clinical-development strategies, trial budgets, regulatory submissions and commercial licensing decisions.

Principle 2 — Structure the board to be effective and add value

Directors should collectively possess appropriate financial, legal, scientific, commercial and risk-management expertise. Independent directors can challenge overly optimistic claims about trial results or a prospective product launch.

Principle 3 — Instil a culture of acting lawfully, ethically and responsibly

The company should maintain a code of conduct, whistleblower policy and anti-bribery framework. In biotech, this should also cover research integrity, patient consent, conflicts of interest, data manipulation and responsible treatment of research participants.

Principle 4 — Safeguard the integrity of corporate reports

Financial statements, trial updates, research milestones and non-audited operational reports require appropriate verification. A scientific milestone must not be described as regulatory approval or proof of clinical efficacy when it is not.

Principle 5 — Make timely and balanced disclosure

Material information must be disclosed in accordance with applicable continuous-disclosure obligations. Trial failures, safety signals, regulatory setbacks, loss of patents or major funding problems may require prompt market disclosure, subject to the applicable legal tests and exceptions.

Principle 6 — Respect the rights of security holders

Investors should have accessible company information, meaningful communication opportunities and appropriate participation in shareholder meetings. Companies should avoid selectively giving material unpublished information to preferred investors.

Principle 7 — Recognise and manage risk

The board should oversee clinical, scientific, cybersecurity, intellectual-property, manufacturing, supply-chain, regulatory and environmental risks. Risk oversight should include realistic assessment of the possibility that trials fail or approval is delayed.

Principle 8 — Remunerate fairly and responsibly

Executive incentives should promote sustainable performance rather than encourage exaggerated claims, premature commercialisation or concealment of adverse results. Equity-based remuneration and any associated hedging policies should be properly governed.

These principles are supported by specific recommendations concerning board composition, reporting integrity, disclosure, risk oversight and remuneration.

Australian Securities Exchange

+1

3. Application to biotechnology companies

A. Board expertise and scientific independence

Biotechnology companies face an unusual governance challenge: directors may understand business strategy without being able to independently evaluate complex scientific claims.

A sound governance structure should therefore include:

Directors with relevant biotechnology, clinical, regulatory and financial experience.

Independent review of significant clinical-development decisions.

A documented process for assessing scientific evidence before market announcements.

Clear separation between scientific advisers' technical opinions and the board's legal and commercial responsibilities.

Conflict-of-interest declarations where directors or executives hold interests in research partners, patent holders or competing businesses.

A scientific advisory board can assist, but it does not replace the directors' statutory duties.

B. Continuous disclosure and clinical-trial announcements

For an ASX-listed biotech firm, clinical-trial information may affect the share price substantially. A governance policy should establish who verifies trial data, who assesses materiality, who authorises announcements and how unpublished information is controlled.

Examples of potentially material developments include:

A primary endpoint not being met.

A serious unexpected safety signal.

A regulator refusing or delaying a critical application.

Withdrawal of a research partner or loss of a key commercial licence.

A substantial reduction in cash runway or inability to finance a planned trial.

The legal question is not whether every research observation must be announced. It is whether the information falls within the applicable disclosure requirements, including ASX Listing Rule 3.1 and its exceptions, and whether public statements risk being misleading.

C. Financial reporting and research expenditure

Early-stage biotech companies may spend substantial funds for years before earning commercial revenue. Governance controls should address:

Cash-flow forecasts and capital-raising assumptions.

Research and development expenditure and accounting treatment.

Going-concern assessments and funding risks.

Impairment of acquired intellectual property and development assets.

Related-party transactions, licensing payments and equity incentives.

Directors cannot simply rely on management or an external auditor without exercising the care and diligence required by law.

D. Ethics, patient safety and regulatory compliance

The board should ensure that the business has suitable compliance systems for the Therapeutic Goods Act 1989 (Cth), applicable TGA requirements, clinical-trial arrangements, privacy law, research ethics and, where relevant, the Gene Technology Act 2000 (Cth).

Depending on the product and activity, other obligations may apply to manufacturing quality, adverse-event reporting, genetically modified organisms, human research and biological materials.

A breach of a scientific or clinical requirement is not automatically a breach of the ASX Principles. However, a serious compliance failure can create corporate risk, trigger disclosure obligations and raise questions about whether directors adequately supervised the company.

4. Important case laws and their application

The following Australian decisions establish principles relevant to ASX-listed biotechnology firms. Some concern general listed-company governance rather than biotechnology specifically; their legal principles nevertheless apply to biotech companies.

Case 1: ASIC v Healey [2011] FCA 717

Subject: Directors' duties and integrity of financial reporting.

The Federal Court considered directors' responsibilities when approving financial statements that contained significant errors relating to liabilities and the companies' financial position.

Legal principle: Directors must exercise their own care and diligence when reviewing financial statements. They cannot simply delegate responsibility for understanding the accounts to management or auditors.

Federal Court of Australia

Application to biotech firms: Directors should independently scrutinise cash reserves, research expenditure, licensing liabilities, impairment of development assets and assumptions underlying the company's ability to continue funding clinical trials.

Case 2: ASIC v Hellicar [2012] HCA 17

Subject: Misleading ASX announcements and directors' duties.

The High Court considered whether directors had breached their duties by approving a misleading announcement concerning the funding of asbestos-related claims. The case emphasised the importance of board decision-making, accurate minutes and directors' responsibility for announcements they approve.

High Court of Australia

+1

Application to biotech firms: If a board approves an announcement describing a therapy as successful or a regulatory milestone as achieved, directors must ensure that the wording is properly supported. Board minutes should accurately document the information considered, qualifications discussed and decisions made.

Case 3: ASIC v Chemeq Ltd [2006] FCA 936

Subject: Continuous disclosure and listed-company compliance systems.

This decision is relevant to the governance of a biotechnology-related business and the consequences of inadequate disclosure controls. ASX Guidance Note 8 refers to the case when discussing the possible relevance of an effective disclosure policy to penalties for disclosure breaches.

Australian Securities Exchange

Application to biotech firms: A company should establish a formal process for escalating material clinical, regulatory and financial information to authorised decision-makers. The policy should be actively implemented, monitored and reviewed rather than merely published on the company's website.

Case 4: TPT Patrol Pty Ltd v Myer Holdings Ltd [2019] FCA 1747

Subject: Continuous disclosure and misleading market statements.

The Federal Court considered claims concerning the failure to disclose material information and the failure to correct a profit forecast. The case illustrates the importance of assessing whether statements about future performance have reasonable grounds and whether omitted information is material.

CaseChat AU

+1

Application to biotech firms: Forward-looking statements about regulatory approval dates, future sales, trial success or commercialisation milestones must be assessed carefully. A forecast should not be presented with unjustified certainty, and changed circumstances may require correction or updated disclosure.

Case 5: ASIC v Adler [2002] NSWSC 171

Subject: Directors' duties, conflicts of interest and misuse of corporate funds.

The New South Wales Supreme Court examined transactions involving HIH Insurance, including conflicts of interest and failures by senior corporate officers to comply with their duties.

Application to biotech firms: Directors and executives should disclose personal interests in licensing arrangements, related-party research transactions, acquisitions and investment decisions. Independent approval and proper documentation help prevent conflicts from undermining corporate decision-making.

Note: These cases should not be read as creating a special ASX biotechnology code. They illustrate general principles of directors' duties, disclosure and reporting that apply to listed biotech firms.

5. Principal legislation and regulatory framework

The current Corporations Act 2001 compilation is available from the Federal Register of Legislation.

Federal Register of Legislation

+1

ASX Guidance Note 8 explains the continuous-disclosure framework and its exceptions.

Australian Securities Exchange

6. Recommended governance model for an ASX-listed biotech firm

A practical governance structure should connect scientific oversight with legal compliance and market disclosure.

Board of directors

Strategy, accountability, risk appetite and statutory duties

Audit and reporting

Financial controls, cash runway and reporting accuracy

Risk and compliance

Clinical, regulatory, biosafety and cyber risks

Scientific oversight

Trial evidence, data integrity and research quality

Disclosure controls

Market announcements and investor communications

Monitoring and accountability

Internal reporting, independent review, whistleblowing and corrective action

This is a recommended structure, not a mandatory ASX organisational chart. A smaller biotech company may combine some functions, provided conflicts are managed and legal obligations are met.

7. Enforcement and potential consequences

Poor governance may result in several different kinds of consequences, depending on the conduct and the applicable legal provisions:

ASIC enforcement: Civil penalty proceedings, disqualification applications or other remedies where statutory requirements are satisfied.

ASX action: Requests for information, trading halts, suspension or other action under applicable Listing Rules.

Shareholder litigation: Claims relating to misleading conduct, disclosure failures or directors' duties, where the legal elements are established.

Regulatory consequences: TGA or gene-technology regulatory action where relevant statutory or regulatory requirements are breached.

Commercial consequences: Loss of investor confidence, difficulty raising capital, impaired licensing negotiations and reputational damage.

A failure to follow an ASX recommendation does not automatically establish statutory liability. Equally, adopting a governance policy does not protect a company if its actual conduct breaches the law.

8. Conclusion

ASX corporate governance for biotechnology firms requires more than conventional financial oversight. It requires a system in which scientific evidence, clinical safety, regulatory compliance, intellectual-property strategy and investor disclosure are integrated into board-level decision-making.

The most important lessons from ASIC v Healey, ASIC v Hellicar, ASIC v Chemeq, TPT Patrol v Myer and ASIC v Adler are that directors must exercise independent judgment, ensure accurate corporate reporting, manage conflicts and maintain reliable processes for disclosing material information.

For an ASX-listed biotech company, the central objective is to protect investors and research participants while enabling scientifically responsible innovation. The board should therefore treat scientific integrity and transparent disclosure as essential elements of corporate governance, not merely technical compliance matters.

Primary reference: ASX Corporate Governance Principles and Recommendations — consult the operative fourth edition and subsequent official updates before applying the framework to a particular reporting period.

This is a general Australian legal research overview, not legal advice on a particular company or proceeding.